Your browser is no longer supported. Please, upgrade your browser.
GSK GlaxoSmithKline plc daily Stock Chart
GlaxoSmithKline plc
Index- P/E135.75 EPS (ttm)0.33 Insider Own0.20% Shs Outstand2.40B Perf Week2.71%
Market Cap108.27B Forward P/E17.24 EPS next Y2.61 Insider Trans0.00% Shs Float2.40B Perf Month6.15%
Income813.80M PEG226.26 EPS next Q0.59 Inst Own8.80% Short Float0.26% Perf Quarter6.40%
Sales32.46B P/S3.34 EPS this Y204.10% Inst Trans0.17% Short Ratio1.77 Perf Half Y14.11%
Book/sh1.53 P/B29.46 EPS next Y14.00% ROA1.10% Target Price47.00 Perf Year11.10%
Cash/sh2.47 P/C18.24 EPS next 5Y0.60% ROE12.20% 52W Range35.12 - 45.45 Perf YTD16.77%
Dividend2.28 P/FCF- EPS past 5Y40.20% ROI41.40% 52W High-0.84% Beta0.82
Dividend %5.06% Quick Ratio0.80 Sales past 5Y-3.40% Gross Margin66.40% 52W Low28.32% ATR0.65
Employees101192 Current Ratio1.10 Sales Q/Q10.80% Oper. Margin7.50% RSI (14)65.47 Volatility1.10% 1.07%
OptionableYes Debt/Eq6.05 EPS Q/Q-96.60% Profit Margin2.50% Rel Volume0.85 Prev Close45.18
ShortableYes LT Debt/Eq5.61 EarningsJul 27 Payout629.40% Avg Volume3.51M Price45.07
Recom2.00 SMA202.76% SMA505.70% SMA20011.85% Volume2,978,330 Change-0.24%
Jul-14-16Upgrade Jefferies Hold → Buy
Mar-30-16Upgrade Citigroup Neutral → Buy
Feb-26-16Initiated Cantor Fitzgerald Hold
Dec-09-15Upgrade BofA/Merrill Neutral → Buy
Dec-07-15Reiterated Argus Buy $52 → $48
Oct-20-15Upgrade Credit Suisse Underperform → Neutral
Sep-15-15Upgrade Exane BNP Paribas Underperform → Neutral
Sep-08-15Upgrade BofA/Merrill Underperform → Neutral
Jun-26-15Upgrade Liberum Sell → Hold
Jun-04-15Downgrade Morgan Stanley Overweight → Equal-Weight
May-20-15Resumed Citigroup Neutral
Apr-15-15Initiated Societe Generale Sell
Feb-19-15Reiterated Argus Buy $55 → $52
Aug-08-14Reiterated Argus Buy $65 → $55
Apr-23-14Upgrade Argus Hold → Buy
May-28-13Upgrade Deutsche Bank Hold → Buy
Jan-11-11Upgrade Jefferies Hold → Buy
Jun-02-10Upgrade Jefferies Hold → Buy
Feb-16-10Upgrade JP Morgan Underweight → Neutral $26
Jan-13-10Downgrade Credit Suisse Outperform → Underperform
Jul-29-16 04:06PM  Veeva Provides The Software In Big Pharma's Race Against The Clock
03:27PM  Legg Mason Introduces International High Dividend, Low Vol ETF
11:04AM  Genvoya Becomes Most Prescribed Regimen for HIV Patients in US
09:12AM  Brexit: GlaxoSmithKline Invests $361M in the UK (GSK) at Investopedia
Jul-28-16 10:59AM  Glaxo (GSK) Beats Q2 Earnings Estimates, Revenues Up Y/Y
05:01AM  AstraZeneca Earnings, Sales Edge Above Forecasts
12:11AM  [$$] GlaxoSmithKline Helped and Hurt by Sterlings Post-Brexit Fall at The Wall Street Journal
Jul-27-16 06:10PM  [$$] GlaxoSmithKline Helped and Hurt by Sterling's Post-Brexit Fall at The Wall Street Journal
12:37PM  Why Fiat Chrysler, Coca-Cola, Anthem and 2 Other Stocks Are Moving Today at Insider Monkey
10:45AM  4 Surprising Quality Growth Stocks That Pay at Least a 5% Dividend at 24/7 Wall St.
10:45AM  McDonalds Joins Glaxo in Giving Jobs Boost to Post-Brexit U.K. at Bloomberg
09:50AM  Stocks Rise At Open As Apple Hauls Techs Higher
09:32AM  GSK invests $A481m in post-Brexit UK AAP
09:21AM  GlaxoSmithKline invests $360 million in UK despite Brexit Reuters
09:14AM  Glaxo reports 2Q loss
09:13AM  GlaxoSmithKline CEO on Performance, Products, Growth at Bloomberg
09:11AM  GlaxoSmithKline CEO: Strong Currency Tailwind Effect at Bloomberg
08:23AM  GlaxoSmithKline Rallies on Strong Quarterly Results
08:20AM  GSK results ride sterling's roller-coaster at CNBC
07:44AM  Should You Buy GlaxoSmithKline After Today's Brilliant Results? at Forbes
07:16AM  GSK outlook brightens as Brexit brings currency windfall
07:07AM  Glaxos Earnings Exceed Estimates, Helped by New Drug Sales at Bloomberg
07:00AM  GSK chases next biotech asthma drug with $230 mln J&J deal
04:20AM  GlaxoSmithKline invests $360 mln in UK despite Brexit vote Reuters
02:03AM  GlaxoSmithKline invests $360 mln in post-Brexit UK manufacturing Reuters
02:00AM  Glaxo to Invest $360 Million in Three U.K. Manufacturing Sites at Bloomberg
Jul-26-16 10:36AM  5 Drug Stocks' Earnings on Jul 27: AMGN, VRTX & More
09:04AM  Newly Acquired Products Boost GlaxoSmithKlines Earnings
Jul-25-16 11:05AM  GSKs Novartis Acquisition Key to Growth in Its Vaccines Segment
11:04AM  How Do the Majority of Analysts Rate Novartis after 2Q16?
09:07AM  GSK 2Q16 Earnings: Did Pharmaceuticals Grow?
08:49AM  Glaxo (GSK) Q2 Earnings: Can the Stock Pull a Surprise?
08:20AM  Time to Sell Utilities, but Time to Buy 3 Other Great Dividends at 24/7 Wall St.
Jul-22-16 04:09PM  GlaxoSmithKline's Sideways Dance May Pay Off in the Long Run
03:39PM  GlaxoSmithKline Segments That Drive Companys Rising Revenues
03:39PM  GSKs HIV Products Expected to Have Driven 2Q Earnings
03:10PM  BioFlash podcast: Why Big Pharma is hungry for bacteria at
01:12PM  Tyvaso Sales Expected to Fall Marginally in 2Q16
10:07AM  Huge Drugmaker Fines for Bribing Healthcare Providers at Motley Fool
Jul-21-16 01:49PM  Inside the Foreign Exchange Impact on Novartiss Growth in 2Q16
01:49PM  How Did Novartiss 2Q16 Earnings Stand up to Analyst Estimates?
Jul-20-16 03:51PM  GSK ships 2016-17 seasonal influenza vaccines for US market PR Newswire
11:00AM  VBIV: A Differentiated Immunology Company With Multiple Near Term Value Drivers
08:42AM  Your inhaler's watching you: drugmakers race for smart devices Reuters
Jul-19-16 07:15PM  Apple Goes After Enormous Medical Technology Market
12:05PM  Where GSK ranks in R&D spending against sales and marketing at
09:04AM  How Do Healthcare Companies Market Their Products? at Motley Fool
Jul-18-16 05:50PM  The iPhone is being used to study rheumatoid arthritis
12:46PM  Why GlaxoSmithKline, Groupon, Lending Club And 2 Micro-Caps Are Trending Today at Insider Monkey
10:49AM  An ETF to Consider for Rebounding U.K. Stocks
09:45AM  Why Novartiss 2Q16 Revenues Are Expected to Fall
09:45AM  Novartiss 2Q16 Earnings: Whats Expected?
08:29AM  ARIA Study Shows Superior Efficacy of Triumeq(R) for Treatment-naive Women Living with HIV PR Newswire
08:15AM  4 High Dividend Yields Close to 5% That Are Often Overlooked at 24/7 Wall St.
06:15AM  ARIA Study Shows Superior Efficacy of Triumeq® for Treatment-naïve Women Living with HIV PR Newswire
Jul-15-16 04:04PM  Why Ionis Pharmaceuticals Inc. Is Surging Today at Motley Fool
Jul-14-16 07:20PM  Halvorsen Funds Company Buying Neglected Drugs, Gets Stakes in 2 Biotechs
11:05AM  ALNY Reports Positive Results from Open Label Extension Study of Revusiran
09:44AM  Glaxo Gains Jefferies Upgrade on Stronger HIV Drugs Performance, Currency Benefits
09:05AM  ALNY Should Complete Revusirans Endeavour Trial Enrollment in Late 2016
07:12AM  GlaxoSmithKline upgraded by Jefferies
03:59AM  European Stocks Rise Ahead of Expected Bank of England Rate Cut
Jul-12-16 05:06PM  The CHMP Just Recommended the Extension of These Drugs Therapeutic Indications
Jul-11-16 03:37PM  Nasdaq Seeks 5,000 Close As Musk Hypes Tesla; Dow's Boeing Jumps
08:41AM  Believe It: Brexit Isn't All Bad For U.K. ETFs
Jul-09-16 05:21PM  Why Dynavax Technologies Shares Slid 12% in June at Motley Fool
09:25AM  Viagra Price Drops 50% as Drug Faces Competition at 24/7 Wall St.
Jul-08-16 08:17AM  Which Big Pharma Is the Best Dividend Stock? at Motley Fool
Jul-06-16 03:38PM  Why Has Brexit Been Bad for Biopharma? at Motley Fool
11:40AM  Corporate Profits in Britain Could Soar, and Brexit Is to Thank at Motley Fool
09:17AM  3 Vaccine Manufacturers That Investors Should Consider for Their Portfolios
12:00AM  The Graying Face of HIV Spurs Race to Simplify Therapies at Bloomberg
Jul-05-16 12:16PM  Is Biopharma Immune to Brexit Fallout? at Motley Fool
Jul-04-16 09:07AM  Pfizers Products with Declining Revenues: What Does That Mean?
Jul-03-16 02:23PM  3 Stocks to Avoid in July at Motley Fool
Jul-02-16 06:44AM  How Post-Brexit Currency Fluctuations Could Affect U.S. ADR Holders at Motley Fool
Jul-01-16 10:00AM  European Stocks: What's Your Pain Tolerance?
08:19AM  Better Buy: GlaxoSmithKline plc vs. Merck at Motley Fool
12:27AM  GSK's Strategy for Growth in Asia
Jun-30-16 01:49PM  New partnership looks to improve lives of children living with HIV at
05:00AM  Why Drug Companies Want to Sell Vaccines to Pregnant Women at Bloomberg
05:00AM  Why Drug Companies Want to Sell Vaccines to Pregnant Women
Jun-29-16 09:07AM  Why Market Share for Novo Nordisks Tresiba Is Set to Grow
Jun-28-16 06:30PM  Which Biotechnology Companies Could Benefit from Brexit?
01:28PM  New Stock Research Reports for June 28, 2016
11:06AM  Mylans Key Developments and Big Plans: What You Should Know
09:27AM  Shire and Glaxo Offer Prescription to London's Woes
Jun-27-16 11:45PM  Regulus Therapeutics Inc. Clinical Hold: Should Investors Be Yellow-Bellied? at Motley Fool
05:31PM  Mylan Launches Generic Version of Glaxo's Avodart in U.S.
09:34AM  How Does Brexit Impact Healthcare Stocks?
08:45AM  These 3 UK business sectors may be hit hard by Brexit at CNBC
08:03AM  6 ways Brexit could impact Washington business at
07:01AM  Effects of Brexit on Pharmaceuticals and the Biotechnology Industry
Jun-24-16 09:04PM  UW researchers compete for $1M prize from GlaxoSmithKline with device for bladder control, sexual function at
02:41PM  Mylan Unveils Generic Avodart Capsules
01:06PM  Post-Brexit Analysis: Should Investors Buy or Sell Biopharma? at Motley Fool
12:50PM  Post-Brexit opportunities in three British stocks at MarketWatch
Jun-23-16 02:47PM  GlaxoSmithKline Has No Cure for Sideways Action
10:57AM  GAVI alliance offers matched funds for GSK malaria vaccine pilot Reuters
Jun-22-16 08:21AM  Can These Upstarts Knock Gilead Sciences Off Its Perch? at Motley Fool
GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company offers pharmaceutical products in the therapeutic areas, including respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health areas. The company's wellness products include Panadol and Panadol Cold & Flu for headache, joint pain, fever, and cold symptoms; ENO and Tums that are immediate relief antacids; and Nicorette (US), Nicoderm, NiQuitin CQ, and Nicabate for the treatment of nicotine withdrawal as an aid to smoking reduction and cessation. Its oral health products comprise Sensodyne to treat and prevent dental sensitivity and acid erosion; Polident, Poligrip, and Corega to enhance comfort of fitted dentures and to clean dentures; and Aquafresh for the prevention of caries, gum disease, and bad breath. The company's nutrition products include Horlicks, a nutritional beverages and food; and skin health products comprise Physiogel, a face and body care product for dry, sensitive, and irritated skin, as well as Zovirax and Abreva to treat and prevent the onset of cold sores. GlaxoSmithKline plc has collaboration agreements with Universite de Sherbrooke and Pfizer Inc.; development agreement, and R and D collaboration with Propeller Health; R and D collaboration agreement with Valneva SE; and collaboration and license agreement with Idera pharmaceuticals, Inc. The company was founded in 1935 and is headquartered in Brentford, the United Kingdom.